Angelini Pharma secures exclusive global license rights to future identified drug targets
Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties
Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
相关新闻
新闻焦点
公司2024年影响力报告展示了在可持续发展方面的重大进展和创新成果洛杉矶--(美国商业资讯)--拥有40年历史的领先消费电子品牌Belkin今日发布了其2024[更多]
First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese Urological As[更多]
文传商讯，中国领先的新闻稿来源，由国际文传（中国）电讯社携手美国商业资讯对外提供。帮助美国商业资讯将其客户的新闻稿呈现给大中华区的目标受众[更多]
热点排行
- PLDA宣布推出Robust Verification Toolset，以提
- Ludovic Blanquet Joins smartTrade as Chief Pro
- Wolters Kluwer FRR Launches OneSumX for Risk M
- 香港旅遊發展局訂立統一衞生防疫指引 向旅客傳遞
- Nanboya香港辦事處遷至佐敦，首個海外採購辦公室
- GSMA Announces Date Changes for its MWC21 Seri
- 罗克韦尔自动化收购网络安全公司
- Standard Digital Group Is Now Accepting Online
- Nanboya香港辦事處遷至佐敦，首個海外採購辦公室
